1. Bener A, Alsulaiman R, Doodson L, Agathangelou T. Depression, hopelessness and social support among breast cancer patients: in highly endogamous population. Asian Pacific journal of cancer prevention: APJCP. 2017;18(7):1889.
2. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. JNCI: Journal of the National Cancer Institute. 2014;106(5).
3. Breast [Internet]. 2018. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/20-Breastfact-sheet.pdf.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.
5. Curado M, Edwards B, Shin H, Storm H, Ferlay J, Heanue H. Cancer incidence in five continents. Lyon: IARC Scientific Publication; 2007.
6. Isfahani P, Hossieni Zare SM, Shamsaii M. The Prevalence of Depression in Iranian Women With Breast Cancer: A Meta-Analysis. The Horizon of Medical Sciences. 2020;26(2):170-81.
7. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biological research. 2017;50(1):33.
8. Piccart M, Hortobagyi GN, Campone M, Pritchard K, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Annals of oncology. 2014;25(12):2357-62.
9. Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. Journal of Clinical Oncology. 2016;34(25):3069-103.
10. Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast cancer: basic and clinical research. 2015;9:BCBCR. S29420.
11. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research. 2009;11(5):R77.
12. Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18). Breast cancer research and treatment. 2020;183(2):419-28.
13. Finn RS, Martin M, Rugo HS, Jones SE, Im S-A, Gelmon KA, et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2–advanced breast cancer (ABC). American Society of Clinical Oncology; 2016.
14. Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, André F, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Annals of Oncology. 2016;27(6):1047-54.
15. Raphael J, Helou J, Pritchard K, Naimark D. Palbociclib in hormone receptor positive advanced breast cancer: a cost-utility analysis. European Journal of Cancer. 2017;85:146-54.
16. Rugo H, Diéras V, Gelmon K, Finn R, Slamon D, Martin M, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Annals of Oncology. 2018;29(4):888-94.
17. Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New England Journal of Medicine. 2016;375(18):1738-48.
18. Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2021;19(2):134-43.
19. Sh R. The costs of breast cancer in the US [Internet]. 2015 [Updated 2015 November 16].
20. Jakka S, Rossbach M. An economic perspective on personalized medicine. The HUGO Journal. 2013;7(1):1-6.
21. Shih Y-CT, Xu Y, Liu L, Smieliauskas F. Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries. Journal of Clinical Oncology. 2017;35(22):2482.
22. Yousuf Zafar S. Financial toxicity of cancer care: it’s time to intervene. Journal of the National Cancer Institute. 2016;108(5):djv370.
23. Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S, et al. Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of oncology: official journal of the European Society for Medical Oncology (2018) 29 7 (1541-1547) PII: S0923-7534 (20) 32578-3). Annals of oncology: official journal of the European Society for Medical Oncology. 2019;30(11).
24. Rugo H, Finn R, Diéras V, Ettl J, Lipatov O, Joy A, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast cancer research and treatment. 2019;174(3):719-29.
25. Tremblay G, Chandiwana D, Dolph M, Hearnden J, Forsythe A, Monaco M. Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer. Cancer management and research. 2018;10:1319.
26. Li J, Huo X, Zhao F, Ren D, Ahmad R, Yuan X, et al. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer A Systematic Review and Meta-analysis. Jama Network Open. 2020;3(10).
27. Galve-Calvo E, González-Haba E, Gostkorzewicz J, Martínez I, Pérez-Mitru A. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain. ClinicoEconomics and outcomes research: CEOR. 2018;10:773.
28. Desnoyers A, Nadler MB, Kumar V, Saleh R, Amir E. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis. Cancer Treatment Reviews. 2020;90:102086.
29. Mamiya H, Tahara R, Tolaney S, Choudhry N, Najafzadeh M. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. Annals of Oncology. 2017;28(8):1825-31.
30. Zhang B, Long EF. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Breast cancer research and treatment. 2019;175(3):775-9.
31. Mistry R, May JR, Suri G, Young K, Brixner D, Oderda G, et al. Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+/HER2-advanced or metastatic breast cancer: a US payer perspective. Journal of managed care & specialty pharmacy. 2018;24(6):514-23.